论文部分内容阅读
[目的]评价CK19,P53,P63,EMA在鉴别甲状腺良恶性(乳头状癌)病变中的临床应用价值;了解甲状腺乳头状癌P170蛋白表达的意义。[方法]通过免疫组织化学方法,检测CK19,P53,P63,EMA,及P170蛋白在38例甲状腺乳头状癌和38例甲状腺良性病变中的表达。[结果]CK19、P53、P63、EMA在甲状腺乳头状癌和良性病变中的阳性率分别为92.1%(35/38)和2.6%(1/38)(P<0.005),89.5%(34/38)和18.4%(7/38)(P<0.005),23.7%(9/38)和10.5%(4/38)(P>0.1),34.2%(13/38)和50%(19/38)(P>0.1)。甲状腺乳头状癌中P170表达阳性率为57.9%(22/38)。[结论](1)CK19和P53是甲状腺乳头状癌病理诊断中非常有价值的辅助诊断指标。(2)甲状腺乳头状癌中P170表达的阳性率与CK19的阳性程度密切相关。
[Objective] To evaluate the clinical value of CK19, P53, P63 and EMA in the differential diagnosis of benign and malignant thyroid (papillary carcinoma) and to understand the significance of P170 protein in thyroid papillary carcinoma. [Methods] The expression of CK19, P53, P63, EMA and P170 protein in 38 cases of thyroid papillary carcinoma and 38 cases of thyroid benign lesions were detected by immunohistochemistry. [Results] The positive rates of CK19, P53, P63 and EMA in thyroid papillary carcinoma and benign lesions were 92.1% (35/38) and 2.6% (1/38) respectively (P <0.005), 89.5% (34/38) 38 and 18.4% (7/38) (P <0.005), 23.7% (9/38) and 10.5% (4/38) 38) (P> 0.1). The positive rate of P170 expression in papillary thyroid carcinoma was 57.9% (22/38). [Conclusion] (1) CK19 and P53 are valuable diagnostic indicators in the pathological diagnosis of papillary thyroid carcinoma. (2) The positive rate of P170 expression in papillary thyroid carcinoma is closely related to the positive degree of CK19.